BioSpace News Archive

InnoCare Pharma announced that Dr. Jasmine Cui, Co-founder, Chairwoman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 10, 2024, U.S. Pacific Standard Time, to update the Company’s latest development.

Opthea Limited announced that it expects to receive the remaining US$35 million committed funds under the Development Funding Agreement with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional US$50 million in funding.

TLC BioSciences announced that the company will present at the 42nd Annual JP Morgan Healthcare Conference at 2:00pm PT on Tuesday, January 9, 2024.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company announced that Janet Rehnquist has been elected to the Company’s Board of Directors where she will chair the compliance and the nominating committees.

Synlogic, Inc. announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab prime contract to develop a manufacturing process to support development of a potential live probiotic product.

Avalo Therapeutics, Inc. announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023.

Algernon Pharmaceuticals Inc. a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on December 12, 2023, from gross proceeds of $150,000 to $280,000 of units at an issue price of $0.075 per Unit.

Novocure announced that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on Wednesday, January 10, 2024.

Zevra Therapeutics, Inc. a rare disease therapeutics company, announced it resubmitted its New Drug Application for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pick disease type C to the U.S. Food and Drug Administration on December 22, 2023.

Matinas BioPharma Holdings, Inc. announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.